QCM
TVTX icon

Quantinno Capital Management’s Travere Therapeutics TVTX Stock Holding History

Quantinno Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.03M Buy
68,317
+53,283
+354% +$1.59M ﹤0.01% 1621
2025
Q4 		$574K Buy
15,034
+1,660
+12% +$54K ﹤0.01% 2280
2025
Q3 		$320K Buy
13,374
+3
+0% +$56 ﹤0.01% 2409
2025
Q2 		$198K Buy
+13,371
New +$222K ﹤0.01% 2370

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quantinno Capital Management's TVTX Position: Q1 2026 in Review

Quantinno Capital Management increased its Travere Therapeutics (TVTX) stake by 354% in Q1 2026, buying an estimated $1.59M and bringing the position to 68,317 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Quantinno Capital Management first reported a position in TVTX in Q2 2025 and has held it in 4 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Quantinno Capital Management held 68,317 shares of Travere Therapeutics worth $2.03M as of Q1 2026.
  • Quantinno Capital Management bought 53,283 Travere Therapeutics shares in Q1 2026, an estimated $1.59M.
  • Travere Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #1621 holding.
  • Quantinno Capital Management first reported a position in Travere Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.